DEA Rescheduling Hearing Puts Cannabis Stocks in Focus Ahead of a July 15 Deadline
The DEA began an expedited hearing on June 29 on whether to move marijuana from Schedule I to Schedule III, with a July 15 conclusion deadline, according to Forbes and Ropes & Gray. An April 23 order already reclassified certain medical cannabis to Schedule III, per Cannabis Business Times. The AdvisorShares Pure US Cannabis ETF MSOS and holdings like Trulieve (TRLV) are highlighted ahead of DOJ’s July 2 response.
How this was made
The 30-second read
Why it matters
The article frames July 2 (DOJ response to a request to stay the April order) and July 15 (hearing conclusion) as the two near-term dates that could move cannabis equities meaningfully, with MSOS already at 2026 highs beforehand.
Market read
This is a catalyst calendar for cannabis equities tied to DEA scheduling and related legal deadlines, with ETF positioning (MSOS) and major holdings (TRLV) used as the transmission mechanism.
What to watch
The text does not quantify probability of rescheduling or specify what evidence will be considered; market moves may hinge more on DOJ/D.C. Circuit procedural developments than on the hearing itself.
Background
The DEA began an expedited hearing June 29 on whether to move marijuana from Schedule I to Schedule III, with a July 15 conclusion deadline; an April 23 order already reclassified certain FDA-approved/state-licensed medical products to Schedule III.
Ticker impact
Trulieve (TRLV) is identified as the largest MSOS holding (~30% of assets), making its equity a direct read-through to rescheduling expectations.
Shares likely track changes in rescheduling probability into July 2 and July 15, with larger moves than the broader sector if expectations swing.
The article links TRLV’s weight in MSOS to the hearing-driven repricing window, even though it does not provide TRLV-specific new fundamentals.
Market effects
A Schedule I to Schedule III decision would extend tax relief beyond medical operators, potentially resetting sector-wide valuation expectations and risk premia.
Primarily U.S.-regulatory driven; could spill over to global cannabis equities via cross-border sentiment and capital flows.
DEA scheduling outcomes can influence international regulators and investor risk appetite for cannabis-related businesses worldwide.
Counterpoint
Even with a hearing, the article emphasizes legal risk and a structured testimony process; outcomes may be delayed or constrained, limiting how much the sector can reprice by July 15.
Key entities
- regulatorDEA
Holds an expedited hearing to decide whether marijuana should be moved from Schedule I to Schedule III, concluding by July 15.
- ETFAdvisorShares Pure US Cannabis ETF (MSOS)
Cannabis-focused ETF cited as having hit 2026 highs ahead of the hearing; largest holding is Trulieve.
- cannabis operatorTrulieve
Largest MSOS holding (~30% of assets) and subject to rescheduling read-through via ETF flows.
- cannabis operatorCuraleaf
Completed a 1-for-3 reverse split around June 5 to prepare for a potential U.S. exchange uplisting.
